BRPI0606817A2 - derivados de piridazina e seu uso como agentes terapêuticos - Google Patents
derivados de piridazina e seu uso como agentes terapêuticosInfo
- Publication number
- BRPI0606817A2 BRPI0606817A2 BRPI0606817-0A BRPI0606817A BRPI0606817A2 BR PI0606817 A2 BRPI0606817 A2 BR PI0606817A2 BR PI0606817 A BRPI0606817 A BR PI0606817A BR PI0606817 A2 BRPI0606817 A2 BR PI0606817A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyridazine derivatives
- therapeutic agents
- mammal
- formula
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Abstract
DERIVADOS DE PIRIDAZINA E SEU USO COMO AGENTES TERAPêUTICOS. Métodos de tratamento de uma doença ou condição mediada por SCD em um mamífero, preferivelmente um ser humano, são descritos, em que os métodos compreendem administrar a um mamífero em necessidade deste um composto de acordo com a fórmula (Ia): onde x, y, W, V, R², R³, R^ 4^, R^ 5^, R^ 6^, R^ 6a^, R^ 7^ R^ 7a^ R^ 8^ R^ 8a^ R^ 9^ e R^ 9a^ são definidos aqui. Composições farmacêuticas compreendendo os compostos de fórmula (I) são também descritas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/055,034 US7754711B2 (en) | 2003-07-30 | 2005-02-09 | Pyridazine derivatives and their use as therapeutic agents |
PCT/US2006/004389 WO2006086447A2 (en) | 2005-02-09 | 2006-02-08 | Pyridazine derivatives and their use as therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0606817A2 true BRPI0606817A2 (pt) | 2009-07-14 |
Family
ID=36646207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0606817-0A BRPI0606817A2 (pt) | 2005-02-09 | 2006-02-08 | derivados de piridazina e seu uso como agentes terapêuticos |
Country Status (16)
Country | Link |
---|---|
US (1) | US7754711B2 (pt) |
EP (1) | EP1851205B1 (pt) |
JP (1) | JP5114212B2 (pt) |
CN (2) | CN101160289A (pt) |
AR (1) | AR052902A1 (pt) |
AT (1) | ATE553096T1 (pt) |
AU (2) | AU2006212763A1 (pt) |
BR (1) | BRPI0606817A2 (pt) |
CA (1) | CA2597069C (pt) |
ES (1) | ES2385577T3 (pt) |
GT (1) | GT200600045A (pt) |
MX (1) | MX2007009593A (pt) |
MY (1) | MY141939A (pt) |
PE (2) | PE20061065A1 (pt) |
TW (1) | TWI320316B (pt) |
WO (1) | WO2006086447A2 (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050119251A1 (en) * | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
US7759348B2 (en) * | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
CN101084207A (zh) * | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 |
AU2005286647A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
CA2580845A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
MX2007003318A (es) | 2004-09-20 | 2007-05-18 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
BRPI0515499A (pt) * | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados de piridina para a inibição de estearoil-coa-desaturase humana |
BRPI0515488A (pt) * | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados de heterocìclicos e seu uso como agentes terapêuticos |
MX2007003327A (es) * | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
EP2269610A3 (en) * | 2004-09-20 | 2011-03-09 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
JP5080256B2 (ja) * | 2004-09-20 | 2012-11-21 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 二環式複素環誘導体およびステアロイル−CoAデサチュラーゼ(SCD)のインヒビターとしてのそれらの使用 |
JP2009513563A (ja) * | 2005-06-03 | 2009-04-02 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトのステアロイル−CoAデサチュラーゼ阻害剤としてのアミノチアゾール誘導体 |
RU2009110254A (ru) | 2006-08-24 | 2010-09-27 | Новартис АГ (CH) | Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений |
WO2008029266A1 (en) * | 2006-09-08 | 2008-03-13 | Glenmark Pharmaceuticals S.A. | Stearoyl coa desaturase inhibitors |
EP2076509A4 (en) * | 2006-10-20 | 2011-02-16 | Merck Frosst Canada Ltd | AZACYCLOALCANE DERIVATIVES AS DELTA-9 DEATURASE STEAROYL COENZYME INHIBITORS |
WO2008062276A2 (en) * | 2006-11-20 | 2008-05-29 | Glenmark Pharmaceuticals S.A. | Acetylene derivatives as stearoyl coa desaturase inhibitors |
TW200826936A (en) | 2006-12-01 | 2008-07-01 | Merck Frosst Canada Ltd | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
AR064965A1 (es) | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
WO2008096746A1 (ja) | 2007-02-06 | 2008-08-14 | Takeda Pharmaceutical Company Limited | スピロ化合物およびその用途 |
CA2685266C (en) | 2007-04-27 | 2014-01-28 | Purdue Pharma L.P. | Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal |
WO2008157844A1 (en) * | 2007-06-21 | 2008-12-24 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
WO2009037542A2 (en) | 2007-09-20 | 2009-03-26 | Glenmark Pharmaceuticals, S.A. | Spirocyclic compounds as stearoyl coa desaturase inhibitors |
US20100160323A1 (en) * | 2008-12-23 | 2010-06-24 | Alexander Bischoff | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE |
AU2010215035B2 (en) | 2009-02-17 | 2014-06-12 | Merck Canada Inc. | Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
US8383643B2 (en) | 2009-07-28 | 2013-02-26 | Merck Canada Inc. | Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
WO2011030312A1 (en) | 2009-09-10 | 2011-03-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES |
EP2723732B1 (en) | 2011-06-22 | 2017-01-18 | Purdue Pharma LP | Trpv1 antagonists including dihydroxy substituent and uses thereof |
CN104768549A (zh) | 2012-05-22 | 2015-07-08 | 耶路撒冷希伯来大学的益生研究开发有限公司 | 未分化细胞的选择性抑制剂 |
US10703712B2 (en) | 2015-09-16 | 2020-07-07 | Metacrine, Inc. | Farnesoid X receptor agonists and uses thereof |
KR20190108118A (ko) | 2017-01-06 | 2019-09-23 | 유마니티 테라퓨틱스, 인크. | 신경계 장애의 치료를 위한 방법 |
IL269068B (en) | 2017-03-15 | 2022-09-01 | Metacrine Inc | Paranoid x receptor agonists and uses thereof |
IL269065B (en) | 2017-03-15 | 2022-09-01 | Metacrine Inc | Paranoid x receptor agonists and uses thereof |
CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
KR20210076910A (ko) | 2018-09-18 | 2021-06-24 | 메타크린, 인크. | 파르네소이드 x 수용체 효능제 및 그의 용도 |
BR112021018591A2 (pt) * | 2019-03-22 | 2021-11-23 | Yumanity Therapeutics Inc | Compostos e usos dos mesmos |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5001125A (en) | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
ES8802151A1 (es) | 1985-07-31 | 1988-04-01 | Janssen Pharmaceutica Nv | Un procedimiento para la preparacion de nuevos piridazinaminas. |
MY104343A (en) | 1987-11-23 | 1994-03-31 | Janssen Pharmaceutica Nv | Novel pyridizinamine deravatives |
US5883094A (en) * | 1995-04-24 | 1999-03-16 | Pfizer Inc. | Benzimidazolone derivatives with central dopaminergic activity |
DK0876366T3 (da) * | 1996-01-15 | 2001-11-05 | Janssen Pharmaceutica Nv | Angiogenese-inhiberende pyridazinaminer |
DE19614204A1 (de) | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
AU8096798A (en) | 1997-06-27 | 1999-01-19 | Resolution Pharmaceuticals Inc. | Dopamine d4 receptor ligands |
US6677452B1 (en) | 1999-09-30 | 2004-01-13 | Lion Bioscience Ag | Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof |
WO2001062954A2 (en) * | 2000-02-24 | 2001-08-30 | Xenon Genetics, Inc. | Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
DE60130771T2 (de) | 2000-07-27 | 2008-07-17 | Eli Lilly And Co., Indianapolis | Substituierte heterocyclische amide |
CA2430987A1 (en) | 2000-09-26 | 2002-04-04 | Xenon Genetics, Inc. | Methods and compositions employing a novel stearoyl-coa desaturase-hscd5 |
JP4186518B2 (ja) * | 2001-06-15 | 2008-11-26 | アステラス製薬株式会社 | フェニルピリジン誘導体 |
EP1396487B1 (en) | 2001-06-15 | 2008-12-10 | Astellas Pharma Inc. | Phenylpyridine carbonyl piperazine derivative |
FR2827604B1 (fr) * | 2001-07-17 | 2003-09-19 | Sanofi Synthelabo | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
EP1474401A2 (en) * | 2002-02-05 | 2004-11-10 | Novo Nordisk A/S | Novel aryl- and heteroarylpiperazines |
EA007099B1 (ru) | 2002-03-13 | 2006-06-30 | Янссен Фармацевтика Н. В. | Сульфонилпроизводные в качестве ингибиторов гистон-деацетилазы |
CN100519527C (zh) | 2002-03-13 | 2009-07-29 | 詹森药业有限公司 | 组织蛋白去乙酰酶抑制剂 |
AU2003236500B9 (en) * | 2002-06-12 | 2009-07-02 | Chemocentryx, Inc. | 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders |
US7262194B2 (en) * | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
US20040024658A1 (en) | 2002-08-05 | 2004-02-05 | General Electric Company | System and method for providing asset management and tracking capabilities |
US7582635B2 (en) * | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
EP2316827B1 (en) * | 2003-07-30 | 2016-01-27 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
JP4838128B2 (ja) | 2003-07-30 | 2011-12-14 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ピペラジン誘導体および治療剤としてのその用途 |
BRPI0412343A (pt) | 2003-07-30 | 2006-09-05 | Xenon Pharmaceuticals Inc | derivados de piridazina e seu uso como agentes terapêuticos |
AU2005286647A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
AU2006272334A1 (en) * | 2005-07-20 | 2007-01-25 | Merck Frosst Canada Ltd | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
-
2005
- 2005-02-09 US US11/055,034 patent/US7754711B2/en not_active Expired - Fee Related
-
2006
- 2006-02-07 GT GT200600045A patent/GT200600045A/es unknown
- 2006-02-08 CA CA2597069A patent/CA2597069C/en not_active Expired - Fee Related
- 2006-02-08 ES ES06748193T patent/ES2385577T3/es active Active
- 2006-02-08 AT AT06748193T patent/ATE553096T1/de active
- 2006-02-08 AU AU2006212763A patent/AU2006212763A1/en not_active Abandoned
- 2006-02-08 MX MX2007009593A patent/MX2007009593A/es active IP Right Grant
- 2006-02-08 WO PCT/US2006/004389 patent/WO2006086447A2/en active Application Filing
- 2006-02-08 CN CNA2006800097087A patent/CN101160289A/zh active Pending
- 2006-02-08 EP EP06748193A patent/EP1851205B1/en not_active Not-in-force
- 2006-02-08 CN CN201210057740XA patent/CN102600162A/zh active Pending
- 2006-02-08 JP JP2007555182A patent/JP5114212B2/ja not_active Expired - Fee Related
- 2006-02-08 BR BRPI0606817-0A patent/BRPI0606817A2/pt not_active IP Right Cessation
- 2006-02-08 MY MYPI20060535A patent/MY141939A/en unknown
- 2006-02-09 AR ARP060100466A patent/AR052902A1/es unknown
- 2006-02-09 PE PE2006000153A patent/PE20061065A1/es not_active Application Discontinuation
- 2006-02-09 PE PE2010000343A patent/PE20100561A1/es not_active Application Discontinuation
- 2006-02-09 TW TW095104384A patent/TWI320316B/zh not_active IP Right Cessation
-
2010
- 2010-10-06 AU AU2010227003A patent/AU2010227003B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
WO2006086447A3 (en) | 2007-04-05 |
AU2010227003A1 (en) | 2010-10-28 |
TWI320316B (en) | 2010-02-11 |
MY141939A (en) | 2010-07-30 |
GT200600045A (es) | 2006-09-13 |
CA2597069A1 (en) | 2006-08-17 |
MX2007009593A (es) | 2007-10-16 |
AR052902A1 (es) | 2007-04-11 |
WO2006086447A2 (en) | 2006-08-17 |
CA2597069C (en) | 2011-09-20 |
US7754711B2 (en) | 2010-07-13 |
ATE553096T1 (de) | 2012-04-15 |
ES2385577T3 (es) | 2012-07-26 |
CN102600162A (zh) | 2012-07-25 |
PE20100561A1 (es) | 2010-08-25 |
TW200638935A (en) | 2006-11-16 |
AU2010227003B2 (en) | 2012-06-14 |
AU2006212763A1 (en) | 2006-08-17 |
CN101160289A (zh) | 2008-04-09 |
EP1851205B1 (en) | 2012-04-11 |
PE20061065A1 (es) | 2006-12-01 |
JP5114212B2 (ja) | 2013-01-09 |
EP1851205A2 (en) | 2007-11-07 |
US20060009459A1 (en) | 2006-01-12 |
JP2008530098A (ja) | 2008-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0606817A2 (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
BRPI0412343A (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
BRPI0515488A (pt) | derivados de heterocìclicos e seu uso como agentes terapêuticos | |
BRPI0515482A (pt) | derivados heterocìclicos e seus usos como agentes terapêuticos | |
BRPI0515477A (pt) | derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd) | |
BRPI0515500A (pt) | derivados piridazina para inibição de estearoil-coa-desaturase | |
BRPI0515489A (pt) | derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase | |
NO20060981L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
BRPI0418939A (pt) | derivados de nicotinamida e sua utilização como agentes terapêuticos | |
BRPI0412348A (pt) | derivados de piperazina e seu uso como agentes terapêuticos | |
BRPI0515483A (pt) | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase | |
WO2007046867A3 (en) | Piperidine derivatives and their uses as therapeutic agents | |
BRPI0514357A (pt) | combinações para o tratamento de doenças que envolvem a proliferação de células | |
BRPI0515505A (pt) | derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase | |
WO2007046868A3 (en) | Thiazolidine derivatives and their uses as therapeutic agents | |
BRPI0413059A (pt) | derivados de piridila e seu uso como agentes terapêuticos | |
NO20080408L (no) | Azaindazolforbindelser og anvendelse derav | |
WO2007044085A3 (en) | Heteroaryl compounds and their uses as therapeutic agents | |
NO20074391L (no) | CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
NO20064201L (no) | Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling | |
ATE557015T1 (de) | 3,4-diarylpyrazole als proteinkinaseinhibitoren | |
BRPI0515499A (pt) | derivados de piridina para a inibição de estearoil-coa-desaturase humana | |
BRPI0518231A2 (pt) | derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica | |
ECSP099177A (es) | Derivados de quinazolinona e isoquinolinona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2364 DE 26-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |